Pfizer and Lilly announced positive results from a study evaluating tanezumab, an investigational humanized monoclonal antibody, for the treatment of OA pain.
The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10 mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of trimethoprim-sulfamethoxazole for a bacterial skin infection.
The FDA has approved updated labeling for Cosentyx that includes data demonstrating that the drug slows the progression of joint structural damage in patients with active psoriatic arthritis.
The FDA has approved use of Prolia for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture.
Early treatment of undifferentiated arthritis may delay progression to rheumatoid arthritis.
Bisphosphonates did not show to be beneficial for patients with knee osteoarthritis.
The FDA has approved Durolane for treatinf pain from knee OA.
Updated guidelines for chronic, non-cancer pain focus on safe and effective opioid prescribing practices.
Siliq will carry a Black Box Warning and is available only through a restricted program.